Le Lézard
Classified in: Health, Science and technology, Business
Subjects: ERN, PER

Stealth BioTherapeutics Reports First Half 2019 Financial Results And Recent Business Highlights

BOSTON, Aug. 14, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the three and six months ended June 30, 2019 and provided a corporate update, including the announcement of a new Board member, Dr. Louis G. Lange.

"As we move into the second half of 2019, we look forward to achieving key near-term milestones including completion of our Phase 3 study of elamipretide in primary mitochondrial myopathy, clarification around the path to registration for our Barth program, and progression of our next product candidate, SBT-272, into the clinic," said Reenie McCarthy, Chief Executive Officer.  "We're also delighted to welcome Lou Lange to our Board of Directors, where his extensive scientific, industry, operating and investment experience will augment our efforts to bring first-in-class therapies to patients with rare mitochondrial diseases."

Recent Highlights

Other posters included presentations on the TAZPOWER design, TAZPOWER data, primary mitochondrial myopathy natural history, primary mitochondrial myopathy open-label extension data, and MMPOWER primary mitochondrial myopathy Phase 1/2 metabolomics data.

Key Upcoming Milestones

Financial Results for the Six Months Ended June 30, 2019

Cash Position: Cash and cash equivalents were $53.2 million at June 30, 2019, compared to $10.9 million at December 31, 2018.  In February 2019, the Company raised $76.9 million in net proceeds from its initial public offering (IPO).

Research and Development (R&D) Expenses: R&D expenses were $23.7 million for the six months ended June 30, 2019, compared to $25.5 million for the six months ended June 30, 2018.  The decrease was primarily due to a $5.4 million decrease in clinical trial costs due to timing of trials that ended in 2018 and a $0.5 million decrease in discovery related expenses due to timing of activities, offset in part by increases of $1.6 million in headcount,  $1.4 million in consulting related expenses related to the continued build-out of clinical, medical affairs and regulatory functions, and a $1.1 million increase in contract manufacturing expenses for NDA-enabling activities.

General and Administrative (G&A) Expenses: G&A expenses were $10.2 million for the six months ended June 30, 2019, compared to $7.8 million for the six months ended June 30, 2018. The increase in administrative expenses was primarily attributable to an increase of $1.3 million in pre-commercial activities including market awareness and payer reimbursement activities, a $0.7 million increase in professional services for activities attributable to operating as a public company, and a net $0.4 million increase in headcount and consulting related expenses.

Other Expense, Net: Other expense for the six months ended June 30, 2019 was $25.0 million, compared to $14.1 million for the six months ended June 30, 2018.  The increase in other expense is primary attributable to a $22.7 million loss on extinguishment of debt recorded in conjunction with the IPO, offset by an $8.8 million change period over period in the fair value adjustments of the derivative liability associated with the convertible debt and a decrease in interest expense mostly related to the convertible debt of $2.9 million.

Net Loss: Net loss for the six months ended June 30, 2019 was $58.9 million, or $0.18 basic and diluted net loss per ordinary share, as compared to $47.4 million for the comparable period of 2018, or $0.69 basic and diluted net loss per ordinary share.  

About Stealth

We are a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases, collectively known as primary mitochondrial diseases, and are also involved in many common age-related diseases. We believe our lead product candidate, elamipretide, has the potential to treat both rare genetic and common age-related mitochondrial diseases. We are studying elamipretide in the following primary mitochondrial diseases: primary mitochondrial myopathy, Barth syndrome and Leber's hereditary optic neuropathy. We are also studying elamipretide in dry age-related macular degeneration. Our other pipeline candidates include SBT-272, which we are evaluating for rare neurodegenerative disease indications, and SBT-20, which we are evaluating for rare peripheral neuropathies. We have optimized our discovery platform to identify novel mitochondrial-targeted compounds, which may be nominated as therapeutic product candidates or utilized as scaffolds to deliver other compounds to mitochondria. We have assembled a highly experienced management team, board of directors and group of scientific advisors to help us achieve our mission of leading mitochondrial medicine.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Stealth BioTherapeutics' plans, strategies and expectations for its preclinical and clinical advancement of its drug development programs, including its ongoing clinical trials of elamipretide and planned clinical trial of SBT-272; the potential benefits of Stealth BioTherapeutics' product candidates; its key milestones for 2019; and its plans regarding future data presentations and regulatory interactions. Statements that are not historical facts, including statements about Stealth BioTherapeutics' beliefs, plans and expectations, are forward-looking statements. The words "anticipate," "expect," "hope," "plan," "potential," "possible," "will," "believe," "estimate," "intend," "may," "predict," "project," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Stealth BioTherapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of known and unknown risks, uncertainties and other important factors, including: Stealth BioTherapeutics' ability to obtain additional funding; the ability to successfully demonstrate the efficacy and safety of Stealth BioTherapeutics' product candidates and future product candidates; the preclinical and clinical results for Stealth BioTherapeutics' product candidates, which may not support further development and marketing approval; the potential advantages of Stealth BioTherapeutics' product candidates; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, which may affect the initiation, timing and progress of preclinical studies and clinical trials of Stealth BioTherapeutics' product candidates; Stealth BioTherapeutics' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Stealth BioTherapeutics' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Stealth BioTherapeutics' most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC"), as well as in any future filings with the SEC. Forward-looking statements represent management's current expectations and are inherently uncertain. Except as required by law, Stealth BioTherapeutics does not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

Media Relations
dna Communications
Lindsey Colegrove, 212-537-8771

Investor Relations
Stern Investor Relations
Lauren Stival, 212-362-1200




Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)


Three Months Ended June 30,

Six Months Ended June 30,





Operating expenses:

Research and development

$         9,366

$       12,100

$       23,694

$       25,536

General and administrative





Total operating expenses





Loss from operations





Other income (expense):

Loss on extinguishment of debt





Change in fair value of derivative liability





Change in fair value of warrant liability





Interest expense





Interest income





Total other income (expense)





Net loss attributable to ordinary shareholders

$      (15,750)

$      (27,057)

$      (58,928)

$      (47,398)

Net loss per share attributable to ordinary shareholders ? basic and diluted

$          (0.04)

$          (0.40)

$          (0.18)

$          (0.69)

Weighted average ordinary shares used in net loss per share attributable to ordinary
shareholders ? basic and diluted








Condensed Consolidated Balance Sheets

(in thousands)


June 30,

December 31, 




Current assets:

Cash and cash equivalents

$       53,200

$       10,855

Prepaid expenses and other current assets



Total current assets



Property and equipment, net



Deferred offering costs



Other non-current assets



Total assets

$       55,295

$       15,523

Liabilities, convertible preferred shares and shareholders' equity (deficit)

Current liabilities:

Accounts payable

$         8,970

$       11,023

Accrued expenses and other current liabilities



Accrued interest payable



Current portion of long-term debt



Total current liabilities



Long-term debt, less current portion



Convertible notes payable



Derivative liability



Warrant liability



Total liabilities



Series A convertible preferred shares



Total shareholders' equity (deficit)



Total liabilities, convertible preferred shares and shareholders' equity (deficit)

$       55,295

$       15,523


SOURCE Stealth BioTherapeutics

These press releases may also interest you

at 19:07
Today's media coverage of the labour dispute between CUPE 7000 and the BCRTC (SkyTrain) included interviews with a TransLink spokesperson whose inaccurate statements and incendiary language directed at the union do nothing to move the parties closer...

at 15:35
In keeping with 20 years of holiday tradition, Sunday River held its annual Santa Sunday event today. 240 Saint Nicks skied and snowboarded down the Maine ski area's slopes to raise $6,2000 for The River Fund, which is the highest fundraising total...

at 12:30
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Net 1 UEPS Technologies, Inc. between September 12, 2018 and November 8, 2018, inclusive (the "Class...

at 12:10
Compare-autoinsurance.org has launched a new blog post that explains how policyholders can save car insurance money if they bundle multiple policies. For more info and free quotes, please visit...

at 11:10
Cheapquotesautoinsurance.com has released a new article that explains how teens can get cheap car insurance. For more info and free car insurance quotes, visit http://cheapquotesautoinsurance.com/how-to-make-teen-car-insurance-cheaper/ It is a...

at 10:10
Carinsuranceplan.org has released a new blog post that presents the top reasons for installing tracking devices and how these can help drivers save car insurance money. For more info and free quotes, visit...

News published on 14 august 2019 at 16:20 and distributed by: